



Antibiotic Resistance Among *Helicobacter pylori* Strains Isolated from Patients with Histopathological Changes of the Gastric Tissue Towards Metronidazole, Clarithromycin, and Ciprofloxacin

Saeed Bayati¹, Nour Amirmozafari^{1*}, Masoud Alebouyeh^{2,3,**}, Nastaran Farzi², Nasser Ebrahimi Daryani⁴ and Mohammad Reza Zali⁵

¹Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

²Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³Pediatric Infections Research Center (PIRC), Research Institute for Children Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁴Department of Gastroenterology and Hepatology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

⁵Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Science, Tehran, Iran

*Corresponding author: Professor, Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Email: amirmozafari@iums.ac.ir

**Corresponding author: Assistant Professor, Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Tel: +982122432518, Fax: +982122432518, Email: masoud.alebouyeh@gmail.com

Received 2017 June 14; Revised 2018 October 09; Accepted 2018 October 28.

Abstract

Background: The extent of antibiotic resistance among *Helicobacter pylori* strains influences current clinical therapeutic regimens in each region.

Objectives: This cross-sectional study aimed to determine the resistance property and minimum inhibitory concentration (MIC₅₀₋₉₀) of *Helicobacter pylori* strains toward metronidazole, clarithromycin, and ciprofloxacin in patients with distinct gastric histopathological changes in Tehran, Iran.

Methods: This study was conducted on 170 patients suffering from gastric complications in three hospitals in Tehran from October 2014 until March 2015. Two separate biopsy samples were collected from each patient and used for pathological and microbiological examinations. Antimicrobial susceptibility tests were performed by agar dilution method according to the CLSI guidelines. The MIC values and susceptibility to varying concentrations of metronidazole (4 to 64 µg/mL), ciprofloxacin (0.5 to 16 µg/mL), and clarithromycin (0.25 to 16 µg/mL) were determined based on EUCAST recommendations.

Results: Our results indicated the infection with *H. pylori* in a frequency of 32% (55/170) among the study patients (female, 51% and male, 49%). Endoscopic findings indicated that 42% of the patients suffered from peptic ulcers, 33% from duodenal ulcers, and 25% with a non-ulcer disease. Pathological findings indicated 58% of the patients had chronic gastritis, 33% had active chronic gastritis, and 9% suffered from intestinal metaplasia. In terms of antibiotic susceptibility, nearly 76.3%, 49%, and 45.5% of the strains were resistant to metronidazole, clarithromycin, and ciprofloxacin, respectively. The MIC values at which the growth of 50% and 90% of the strains was inhibited (MIC₅₀₋₉₀) were 32 - 64 µg/mL for metronidazole, 0.5 - 16 µg/mL for clarithromycin, and 2 - 16 µg/mL for ciprofloxacin.

Conclusions: The overall resistance levels were relatively high among the study patients. Accordingly, the administration of other anti-*Helicobacter* drugs, as well as more appropriate therapeutic regimens based on laboratory results, is recommended in patients with a history of treatment failure.

Keywords: *Helicobacter pylori*, Antimicrobial Resistance, Histopathological Changes, Minimum Inhibitory Concentration

1. Background

Helicobacter pylori is a microaerophilic Gram-negative bacterium that resides within gastric mucosa. It is responsible for a variety of gastric and extra-gastrointestinal diseases (1, 2). Although in some developing countries, its prevalence is as high as 80% - 90%, lower rates of infection

are reported from developed countries (3). Many different therapeutic regimens are used in order to eradicate *H. pylori* infection and prevent the development of drug resistance. The standard triple therapy includes amoxicillin in combination with either metronidazole or clarithromycin and a proton pump inhibitor (4). Resistance to antimicrobial drugs is a major cause of treatment failure and

is largely responsible for the decline in eradication rates. Other regimens that have been used so far in patients with *H. pylori* infection include second-line therapy, sequential therapy, and concomitant therapy (5-7). In these regimens, alternative antibiotics such as ciprofloxacin, rifampin, and tetracycline are used. Clinical trials have demonstrated that the degree of *H. pylori* eradication using the same regimen is much lower in most developing countries than in developed countries (8). There are numerous reports regarding the resistance of clinical isolates of *H. pylori* to antibiotics used in first-line therapy (e.g. metronidazole and clarithromycin) in Iran (9). Therefore, there seems to be a need to use other drugs, such as ciprofloxacin, in alternative therapeutic regimens (e.g. levofloxacin triple therapy). Due to the lack of laboratory-based evidence of assessing the susceptibility of *H. pylori* strains to ciprofloxacin compared to metronidazole and clarithromycin, we decided to investigate the levels of resistance towards these drugs in the current study so that a newer, more effective therapeutic regimen could be proposed.

2. Objectives

This cross-sectional study aimed to determine the resistance property and minimum inhibitory concentration (MIC₅₀₋₉₀) of *Helicobacter pylori* strains toward metronidazole, clarithromycin, and ciprofloxacin in patients with distinct gastric histopathological changes in Tehran, Iran.

3. Methods

3.1. Patients and Bacterial Strains

This cross-sectional study was conducted on 170 patients suffering from gastric complications in Laleh, Kasra, and Behbood hospitals in Tehran, Iran, from October 2014 until March 2015. Patients with a recent history of anti-*H. pylori* therapy were excluded from this study. This investigation was approved by the Ethics Committee of Iran University of Medical Sciences (code: 02-9324745-30). A standard questionnaire was used to collect demographic data, including age, gender, smoking behavior, and relevant clinical data. All the patients announced their agreement with the study by signing informed consent forms. Pathological results were provided by the pathological departments of the selected hospitals according to the updated Sydney system. The presence of gastric and duodenal ulcers was determined by gastroenterologists after endoscopy.

3.2. Isolation and Identification of *Helicobacter pylori*

Two separate biopsy samples were obtained from the antrum of each patient, one for microbiological culture, and the other for pathology. The samples were placed in thioglycollate transport medium and then transferred to the *Helicobacter* laboratory at the Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. After homogenization, the samples were cultured on Brucella agar (Merck, Germany) with defibrinated sheep blood (5%), fetal calf serum (10%), supplement (Merck, Homburg, Germany), and amphotericin B (Sigma-Aldrich, USA) (2 mg/L). The plates were incubated at 37°C in a microaerophilic atmosphere for 3 - 7 days. Any grown colonies were Gram stained and, for species identification, subjected to urease, oxidase, and catalase tests and polymerase chain reaction (PCR) using species-specific primer sets (10). The reaction was performed in a final volume of 25 µL. The PCR was performed in a thermocycler (AG 22331; Eppendorf, Hamburg, Germany) under the following conditions: initial denaturation for 5 min at 94°C, followed by 30 cycles of 93°C for 1 min, 58°C for 30 s, and 72°C for 1 min (10). Strain RIGLD-OC4 was used as a positive control.

3.3. Antibiotic Susceptibility Tests

The agar dilution method recommended by CLSI (11) was used for antibiotic susceptibility testing. Fresh bacterial colonies were transferred to culture in BHI broth (Merck, Germany) until the liquid medium turbidity was equivalent to a 2 McFarland standard. Then, 10 µL of this medium was transferred onto Mueller Hinton agar (Merck, Germany) medium supplemented with defibrinated sheep blood (7%) and different concentrations of antibiotics, metronidazole (4 - 64 µg/mL, Sigma-Aldrich), ciprofloxacin (0.5 - 16 µg/mL, Fluka, USA), and clarithromycin (0.25 - 16 µg/mL, Sigma-Aldrich). The threshold levels for the determination of sensitivity or resistance status were derived from EUCAST (12) guidelines with the borderline levels of > 8 µg/mL for metronidazole, > 1 µg/mL for ciprofloxacin, and > 0.5 µg/mL for clarithromycin. The inoculated plates were incubated in a microaerophilic atmosphere for 48 - 72 h. Minimum inhibitory concentration (MIC) values at which 50% and 90% of the tested strains were inhibited were reported as MIC₅₀ and MIC₉₀, respectively. Strain RIGLD-OC4 was used as a control strain.

3.4. Statistical Analysis

For the analysis of demographic data and the results of antibiotic susceptibility tests, SPSS22 software and Graph-Pad Prism 6 software were used. The chi-square test was

used for variance analysis with a P value of less than 0.05 being significant.

4. Results

4.1. Bacterial Isolation Distribution and Demographic Data

Out of 170 biopsy samples from patients, 55 were found infected with *H. pylori*. All bacterial isolates were confirmed as *H. pylori* based on the tests performed. The age range of the infected patients was 30 - 75 years among whom, 86 were female (51%) and 84 were male (49%). Other demographic data are shown in Table 1. Around 42% of the patients were diagnosed with a peptic ulcer, 33% with duodenal ulcer, and 25% with a non-ulcer disease. Pathological observations indicated that 58% of the patients had chronic gastritis, 33% had severe active gastritis, and 9% were with intestinal metaplasia.

4.2. Antimicrobial Susceptibility Results

The results of MIC for the tested antibiotics showed that 76.3% (42 out of 55) of the isolates were resistant to metronidazole, 49% (27 out of 55) were resistant to clarithromycin, and 45.4% of them were ciprofloxacin resistant (25 out of 55). The degree of resistance to clarithromycin and ciprofloxacin was statistically higher in patients with the age range of 60 - 75 and 45 - 60 years than in other patients. Out of the 55 *H. pylori* isolates, 10 isolates were simultaneously resistant to clarithromycin and metronidazole, three were resistant to both ciprofloxacin and metronidazole, and two were resistant to ciprofloxacin and clarithromycin.

4.3. Minimum Inhibitory Concentration (MIC) Levels

The isolated *H. pylori* strains showed the MIC values of 4 - 64 $\mu\text{g}/\text{mL}$ for metronidazole. The MIC₅₀ and MIC₉₀ levels for metronidazole were 32 and ≥ 64 $\mu\text{g}/\text{mL}$, respectively. Concerning clarithromycin, the MIC was 0.25 - 16 $\mu\text{g}/\text{mL}$ with the MIC₅₀ and MIC₉₀ levels being 0.5 and ≥ 16 $\mu\text{g}/\text{mL}$, respectively. The MIC levels for ciprofloxacin in these strains was 0.5 - 16 $\mu\text{g}/\text{mL}$ and the MIC₅₀ and MIC₉₀ were 2 and ≥ 16 $\mu\text{g}/\text{mL}$, respectively.

4.4. Statistical Relationship Between Demographic Parameters and MIC Values

There was a direct relationship between resistance to clarithromycin and higher ages and acute pathologic ulcers. Additionally, the degree of metronidazole resistance was related to smoking and positive ulcer status (Table 1). Concerning resistance to ciprofloxacin, there seems to be no statistically significant correlation with demographic parameters. The only significant factor was the middle age

group (45 - 60-years-old), in which ciprofloxacin-resistant strains were more prevalent. Furthermore, the MIC values for clarithromycin were higher in the bacteria recovered from higher age groups (≥ 60 -years-old). The MIC ranges of ciprofloxacin and clarithromycin were almost twice in the strains recovered from females and smokers compared to those isolated from men and non-smokers (Table 1).

5. Discussion

The antimicrobial resistance of *H. pylori* strains found in different geographical regions is the direct reflection of their genetic background and the antibiotic therapy commonly used in that region. In this study, the relative abundance of *H. pylori* strains resistant to metronidazole and clarithromycin was significantly higher in those who had active ulcers than in those who did not have ulcers. Wolle et al. reported a similar observation concerning metronidazole-resistant strains (13). In contrast, investigators in China and Taiwan reported almost opposite results (14, 15). The relative usage of metronidazole for parasitic and anaerobic infections may be the reason for the discrepancies. The higher resistance levels toward clarithromycin in the older population can be indicative of earlier treatment failures in chronic infections with subsequent appearance of highly resistant phenotypes. This theory was experimentally proven by Olokoba et al. (16). The extent of metronidazole resistance was detected to be 76% in the current study that was associated with more severe clinical complications; however, in other recent investigations in Iran, this rate was reported from 33% to 78.6% (9). However, in a previous study, no statistically meaningful relationship was found between metronidazole resistance and clinical findings (17). This rate was claimed to be 80% to 100% in Africa and 50% to 95% in Asia (18). The prevalence of *H. pylori* resistance to metronidazole ranges from 20% to 40% in Europe and the USA, with one exception in Northern Italy (19). Additionally, previous studies found no meaningful correlation between metronidazole resistance and patient's sex and age, which was similar to our results. Saracino et al. reported almost similar observations in Italy (20). However, in a single study from India, higher metronidazole resistance rates were reported in women in comparison with male patients (21). The metronidazole MIC in our study was in the range of 4 μg to 64 μg , which was higher than that detected in a European survey performed by Megraud et al. with MIC of 0.05 μg to 32 μg (22), but lower than that reported by An et al. in Korea with 0.08 μg to 512 μg (23). The rate of clarithromycin-resistant strains in this study was found to be 49.1% while other recent investigators in Iran have reported the average range of 22.4% (9). Studies from the USA, Asia, and

Table 1. The Percentage Distribution of MICs in *H. pylori* Strains and Its Relationship with Clinical Findings and Demographic Data

Variable	Resistance to Clarithromycin ^a	P Value	MIC ₅₀ (μg/mL)	Resistance to Metronidazole ^a	P Value	MIC ₅₀ (μg/mL)	Resistance to Ciprofloxacin ^a	P Value	MIC ₅₀ (μg/mL)
Age		0.0004			NS			0.0001	
30 - 45 (n = 25)	5 (20)		0.5	16 (64)		32	7 (28)		2
45 - 60 (n = 21)	15 (71.42)		1	17 (80.9)		16	17 (80.95)		2
60 - 75 (n = 9)	7 (77.77)		1	9 (100)		32	1 (11.11)		2
Sex		NS	0.5		NS				
Female (n = 28)	14 (50)			24 (85.71)		4	14 (50)	NS	0.5
Male (n = 27)	13 (48.14)			18 (66.66)			11 (40.7)		
Smoking		NS			0.0009			NS	
Yes (n = 35)	18 (51.4)		1	32 (91.42)		32	19 (54.2)		4
No (n = 20)	9 (45)		1	10 (50)		32	6 (30)		2
Pathological data		< 0.0001	1		0.01			NS	0.5
CG (n = 32)	8 (25)			20 (62.5)		32	18 (56.2)		
SAG (n = 18)	16 (88.88)			17 (94.4)		16	6 (33.3)		
IM (n = 5)	3 (60)			5 (100)		8	1 (20)		
Endoscopic findings		< 0.001			< 0.0001			NS	
PUD (n = 23)	20 (87)		0.5	23 (100)		16	10 (43.4)		2
DU (n = 18)	3 (17)		2	17 (94.44)		32	9 (50)		8
NUD (n = 14)	4 (28.57)		4	2 (14.28)		16	6 (42.8)		4
Total resistance	27 (49)			42 (76.3)			25 (45.4)		

Abbreviations: CG, chronic gastritis; DU, duodenal ulcer; IM, intestinal metaplasia; NS, not significant; NUD, non-ulcer disease; PUD, peptic ulcer disease; SAG, severe active gastritis.
^a Values are expressed as No. (%).

Europe reported clarithromycin resistance in 29.3%, 18.9%, and 11.1% of the strains, respectively (18). In this study, there was a meaningful correlation between clarithromycin resistance rate and the existence of active ulcers. This correlation was not confirmed in a similar study by Khademi et al. (24). The clarithromycin MICs for the strains isolated in Iran were in the range of 0.016 μg to 256 μg (25). These values are apparently lower than those reported in other countries. Megraud et al. in Europe reported the MICs in the range of 0.05 μg to 128 μg (22). However, the rates in Asian countries were reported to be 0.03 μg to 256 μg (26). In this study, we did not detect any correlation between clarithromycin resistance and patient sex; however, there was a correlation with age. A similar correlation was reported by Ji et al. in China (27). Lower clarithromycin resistance rates in females and peptic ulcer patients compared to males and those who had non-ulcer disease were also reported by De Francesco et al. in Italy (18). The higher prevalence of clarithromycin-resistant strains among those with acute ulcer and metaplasia in our study points to the clinical significance of these strains. Such correlation was not detected in a study by Bai et al. in China (28). Regarding resistance towards ciprofloxacin, the rate observed in this study was 45%; however, other studies from Iran reported it in the range of 2.4% to 65% (9). The resistance rate in our study was much higher than those reported from Europe (7% - 33.9%) and lower than those from Asia (2.6% - 57%) (29). Even though the rates of ciprofloxacin resistance

among patients with gastritis and duodenal ulcers were 24.1% and 20%, respectively, there was no meaningful correlation between resistance rates and clinical parameters (17). Additionally, just like the present study, Llanes et al. in Cuba and Shokrzadeh et al. in Iran found no correlation between ciprofloxacin resistance and patients' gender (30, 31). Lower rates of ciprofloxacin resistance among 60 - 75-year-old patients might be due to the lower rate of ciprofloxacin consumption among these people compared to younger patients. The correlation between patients' age and antibiotic resistance rate has previously been shown for metronidazole by Boyanova et al. (32). They proposed that co-infection with urinary tract infections or respiratory diseases can be considered a risk factor for colonization with ciprofloxacin-resistant strains of *H. pylori*.

5.1. Conclusions

In summary, the results of the investigation indicated a high degree of resistance among Iranian *H. pylori* strains towards metronidazole, ciprofloxacin, and clarithromycin. The earlier administration of second-line antibiotic therapy for *H. pylori*-infected patients may help reduce therapy failure and subsequent affliction with a more serious infection.

Acknowledgments

This paper is part of a MSc thesis financially supported by a grant (No., 24745-30-02-93) from Iran University of Medical Sciences (Tehran, Iran), for which we are very grateful. The study was done in Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Footnotes

Conflict of Interests: There is no conflict of interest.

Ethical Approval: This study was approved by the Ethics Committee of Iran University of Medical Sciences (code: 02-9324745-30).

Funding/Support: This study was supported in part by the Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Patient Consent: All patients announced their agreement with this study by signing informed consent forms.

References

- Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. *Clin Microbiol Rev.* 1997;**10**(4):720-41. [PubMed: 9336670]. [PubMed Central: PMC172942].
- Feldman M, Friedman LS, Brandt LJ. Sleisenger and fortran's. *Gastrointestinal and liver disease.* 8th ed. Philadelphia: Saunders; 2006.
- Lacy BE, Rosemore J. Helicobacter pylori: ulcers and more: The beginning of an era. *J Nutr.* 2001;**131**(10):2789S-93S. doi: 10.1093/jn/131.10.2789S. [PubMed: 11584108].
- Gisbert JP, Calvet X, O'Connor A, Megraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: A critical review. *J Clin Gastroenterol.* 2010;**44**(5):313-25. doi: 10.1097/MCG.0b013e3181c8a1a3. [PubMed: 20054285].
- Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. *Am J Gastroenterol.* 2007;**102**(8):1808-25. doi: 10.1111/j.1572-0241.2007.01393.x. [PubMed: 17608775].
- Kaboli SA, Zojaji H, Mirsattari D, Talaie R, Derakhshan F, Zali MR, et al. Effect of addition of vitamin C to clarithromycin-amoxicillin-omeprazole triple regimen on Helicobacter pylori eradication. *Acta Gastroenterol Belg.* 2009;**72**(2):222-4. [PubMed: 19637777].
- Zojaji H, Talaie R, Mirsattari D, Haghazali M, Molaei M, Mohsenian N, et al. The efficacy of Helicobacter pylori eradication regimen with and without vitamin C supplementation. *Dig Liver Dis.* 2009;**41**(9):644-7. doi: 10.1016/j.dld.2008.09.008. [PubMed: 19493713].
- Saberi-Firooz M, Nejabat M. Experiences with helicobacter pylori treatment in Iran. *Iran J Med Sci.* 2006;**31**(4):181-5.
- Khademi F, Poursina F, Hosseini E, Akbari M, Safaei HG. Helicobacter pylori in Iran: A systematic review on the antibiotic resistance. *Iran J Basic Med Sci.* 2015;**18**(1):2-7. [PubMed: 25810869]. [PubMed Central: PMC4366738].
- Shokrzadeh L, Alebouyeh M, Mirzaei T, Farzi N, Zali MR. Prevalence of multiple drug-resistant Helicobacter pylori strains among patients with different gastric disorders in Iran. *Microb Drug Resist.* 2015;**21**(1):105-10. doi: 10.1089/mdr.2014.0081. [PubMed: 25303151].

- Clinical Laboratory Standards Institute. *Performance standards for antimicrobial susceptibility testing: Seventeenth informational supplement.* Wayne, PA: Clinical and Laboratory Standards Institute; 2007.
- EUCAST. *European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters, Version 2.0, valid from 2012-01-01.* 2012.
- Wolle K, Nilius M, Leodolter A, Muller WA, Malferttheiner P, Konig W. Prevalence of Helicobacter pylori resistance to several antimicrobial agents in a region of Germany. *Eur J Clin Microbiol Infect Dis.* 1998;**17**(7):519-21. [PubMed: 9764558].
- Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. *J Gastroenterol Hepatol.* 2009;**24**(7):1230-5. doi: 10.1111/j.1440-1746.2009.05829.x. [PubMed: 19476562].
- Ching CK, Leung KP, Yung RW, Lam SK, Wong BC, Lai KC, et al. Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. *Gut.* 1996;**38**(5):675-8. [PubMed: 8707111]. [PubMed Central: PMC1383147].
- Olokoba AB, Obateru OA, Bojuwoye MO. Helicobacter pylori eradication therapy: A review of current trends. *Niger Med J.* 2013;**54**(1):1-4. doi: 10.4103/0300-1652.108884. [PubMed: 23661891]. [PubMed Central: PMC3644737].
- Navidifar T, Eslami G, Akhondi M, Baghbanian M, Fallah Zadeh H, Zandi H. Antibacterial resistance patterns of helicobacter pylori clinical isolates from gastric biopsy of patients in Yazd. *Int J Enteric Pathog.* 2014;**2**(2). doi: 10.17795/ijep17791.
- De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide H. pylori antibiotic resistance: A systematic review. *J Gastrointest Liver Dis.* 2010;**19**(4):409-14. [PubMed: 21183333].
- Pilotto A, Rassa M, Leandro G, Franceschi M, Di Mario F, Interdisciplinary Group for the Study of U. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: A multicentre study. *GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis.* 2000;**32**(9):763-8. [PubMed: 11215555].
- Saracino IM, Zullo A, Holton J, Castelli V, Fiorini G, Zaccaro C, et al. High prevalence of primary antibiotic resistance in Helicobacter pylori isolates in Italy. *J Gastrointest Liver Dis.* 2012;**21**(4):363-5. [PubMed: 23256118].
- Gehlöt V, Mahant S, Mukhopadhyay AK, Das K, De R, Kar P, et al. Antimicrobial susceptibility profiles of Helicobacter pylori isolated from patients in North India. *J Glob Antimicrob Resist.* 2016;**5**:51-6. doi: 10.1016/j.jgar.2015.09.009. [PubMed: 27436467].
- Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. *Gut.* 2013;**62**(1):34-42. doi: 10.1136/gutjnl-2012-302254. [PubMed: 22580412].
- An B, Moon BS, Kim H, Lim HC, Lee YC, Lee G, et al. Antibiotic resistance in Helicobacter pylori strains and its effect on H. pylori eradication rates in a single center in Korea. *Ann Lab Med.* 2013;**33**(6):415-9. doi: 10.3343/alm.2013.33.6.415. [PubMed: 24205490]. [PubMed Central: PMC3819440].
- Khademi F, Faghri J, Poursina F, Esfahani BN, Moghim S, Fazeli H, et al. Resistance pattern of Helicobacter pylori strains to clarithromycin, metronidazole, and amoxicillin in Isfahan, Iran. *J Res Med Sci.* 2013;**18**(12):1056-60. [PubMed: 24523796]. [PubMed Central: PMC3908526].
- Keshavarz Azizi Raftar S, Moniri R, Saffari M, Razavi Zadeh M, Arj A, Mousavi SG, et al. The Helicobacter pylori resistance rate to clarithromycin in Iran. *Microb Drug Resist.* 2015;**21**(1):69-73. doi: 10.1089/mdr.2014.0104. [PubMed: 25144338].

26. Aftab H, Miftahussurur M, Subsomwong P, Ahmed F, Khan AK, Yamaoka Y. Helicobacter pylori antibiotic susceptibility patterns in Bangladesh: Emerging levofloxacin resistance. *J Infect Dev Ctries*. 2016;**10**(3):245–53. doi: [10.3855/jidc.7713](https://doi.org/10.3855/jidc.7713). [PubMed: [27031456](https://pubmed.ncbi.nlm.nih.gov/27031456/)].
27. Ji Z, Han F, Meng F, Tu M, Yang N, Zhang J. The association of age and antibiotic resistance of helicobacter pylori: A study in Jiaying City, Zhejiang province, China. *Medicine (Baltimore)*. 2016;**95**(8). e2831. doi: [10.1097/MD.0000000000002831](https://doi.org/10.1097/MD.0000000000002831). [PubMed: [26937912](https://pubmed.ncbi.nlm.nih.gov/26937912/)]. [PubMed Central: [PMC4779009](https://pubmed.ncbi.nlm.nih.gov/PMC4779009/)].
28. Bai P, Zhou LY, Xiao XM, Luo Y, Ding Y. Susceptibility of Helicobacter pylori to antibiotics in Chinese patients. *J Dig Dis*. 2015;**16**(8):464–70. doi: [10.1111/1751-2980.12271](https://doi.org/10.1111/1751-2980.12271). [PubMed: [26147515](https://pubmed.ncbi.nlm.nih.gov/26147515/)].
29. Ghotaslou R, Leylabadlo HE, Asl YM. Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. *World J Methodol*. 2015;**5**(3):164–74. doi: [10.5662/wjm.v5.i3.164](https://doi.org/10.5662/wjm.v5.i3.164). [PubMed: [26413490](https://pubmed.ncbi.nlm.nih.gov/26413490/)]. [PubMed Central: [PMC4572030](https://pubmed.ncbi.nlm.nih.gov/PMC4572030/)].
30. Llanes R, Soria C, Nagashima S, Kobayashi N, Gala A, Guzman D, et al. Phenotypic and genetic characterization of antimicrobial profiles of Helicobacter pylori strains in Cuba. *J Health Popul Nutr*. 2010;**28**(2):124–9. [PubMed: [20411674](https://pubmed.ncbi.nlm.nih.gov/20411674/)]. [PubMed Central: [PMC2980873](https://pubmed.ncbi.nlm.nih.gov/PMC2980873/)].
31. Shokrzadeh L, Jafari F, Dabiri H, Baghaei K, Zojaji H, Alizadeh AH, et al. Antibiotic susceptibility profile of Helicobacter pylori isolated from the dyspepsia patients in Tehran, Iran. *Saudi J Gastroenterol*. 2011;**17**(4):261–4. doi: [10.4103/1319-3767.82581](https://doi.org/10.4103/1319-3767.82581). [PubMed: [21727733](https://pubmed.ncbi.nlm.nih.gov/21727733/)]. [PubMed Central: [PMC3133984](https://pubmed.ncbi.nlm.nih.gov/PMC3133984/)].
32. Boyanova L, Ilieva J, Gergova G, Davidkov L, Spassova Z, Kamburov V, et al. Numerous risk factors for Helicobacter pylori antibiotic resistance revealed by extended anamnesis: A Bulgarian study. *J Med Microbiol*. 2012;**61**(Pt 1):85–93. doi: [10.1099/jmm.0.035568-0](https://doi.org/10.1099/jmm.0.035568-0). [PubMed: [21873378](https://pubmed.ncbi.nlm.nih.gov/21873378/)].